FDA approves Vyepti (eptinezumab-jjmr) as preventative treatment of migraines

Vyepti is a humanised monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand. Approval was based on results from two phase III clinical trials, the PROMISE-1 trial in episodic migraine and the PROMISE-2 trial in chronic migraine.

Biospace Inc.